BioThera Solutions Raises Seed Funding for EV Therapeutics

Ottawa-based BioThera Solutions is advancing its ambitious vision for the future of medicine by seeking $1.5 million USD in seed funding. The company is strategically leveraging its proprietary extracellular vesicle (EV) technology, initially introduced through a high-end skincare serum, as a gateway to groundbreaking therapeutic applications. This funding round, co-supported by the NRC Industrial Research Assistance Program, aims to accelerate production capabilities and fuel international market expansion.

At the core of BioThera's innovation is a novel, scalable method for isolating EVs, microscopic vesicles naturally produced by cells for intercellular communication. Unlike conventional techniques that struggle with industrial-scale output, BioThera claims its patented process can handle significantly larger volumes without compromising the integrity of the EVs. This technological leap is crucial for unlocking the full potential of EVs, which can be engineered to deliver therapeutic payloads, modify gene expression, and influence cellular repair mechanisms.

The company's founder and CEO, Frédéric St-Denis-Bissonnette, a biochemist with extensive academic research in EVs, views the cosmetics sector as a calculated entry point. By focusing on a skincare product derived from aloe vera's naturally abundant EVs, BioThera benefits from a less stringent regulatory pathway. This approach has allowed the company to rapidly secure provisional patents, conduct clinical trials, and gain Health Canada approval for cosmetic use in a fraction of the time typically required for therapeutic development. This strategic maneuver de-risks the technology and provides valuable market validation.

“This is really the technology of the future for medicine,” stated St-Denis-Bissonnette, emphasizing that the skincare line serves as a foundational step. The current serum, which he personally uses, is designed to hydrate and reduce wrinkles, showcasing the immediate benefits of their refined EV formulation. However, the long-term objective is to transition BioThera into a leading contract manufacturer for EVs, catering to the burgeoning demand for these advanced biological delivery systems across various medical fields.

The $1.5 million USD seed round, which will be complemented by non-dilutive funding, is earmarked for scaling manufacturing operations and establishing a global presence. BioThera also plans to file additional patents in key international markets. Furthermore, the company is preparing for a second clinical trial later this year, focusing on the efficacy of its EVs in mitigating irritation from dermatological procedures such as laser treatments and microneedling. This trial will further solidify the therapeutic potential of their EV platform.

St-Denis-Bissonnette has expressed frustration with the investment climate, noting a disparity in funding allocation between biotech ventures like BioThera and AI startups. He believes that with adequate investment, BioThera could have achieved even greater milestones. The company's current focus on demonstrating scientific rigor and educating dermatologists about the benefits of its EV-based serum underscores a commitment to a science-first approach, aiming to build trust and pave the way for broader adoption in both cosmetic and therapeutic arenas.